论文信息 - Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10 - 字舞流文

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

E. Kimby | H. Hawle | S. Rondeau | G. Martinelli | B. Østenstad | S. Dirnhofer | H. Bersvendsen | E. Zucca | M. Bargetzi | A. Ferreri | H. Hagberg | P. Brown | A. Lohri | U. Novak | D. Rauch | U. Mey | B. Wahlin | F. Hitz | M. Hernberg | A. Johansson | T. Zander | W. Mingrone | F. Krasniqi | S. Berardi | S. Demmel